Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Bo Ram | - |
dc.contributor.author | Jeong, Yoon A. | - |
dc.contributor.author | Jo, Min Jee | - |
dc.contributor.author | Park, Seong Hye | - |
dc.contributor.author | Na, Yoo Jin | - |
dc.contributor.author | Kim, Jung Lim | - |
dc.contributor.author | Jeong, So yeon | - |
dc.contributor.author | Yun, Hye Kyeong | - |
dc.contributor.author | Kang, Sanghee | - |
dc.contributor.author | Lee, Dae Hee | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.date.available | 2020-11-02T06:41:00Z | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.issn | 1538-8514 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2215 | - |
dc.description.abstract | Despite an increase in the survival rate of patients with cancer owing to the use of current chemotherapeutic agents, adverse effects of cancer therapies remain a concern. Combination therapies have been developed to increase efficacy, reduce adverse effects, and overcome drug resistance. Genipin is a natural product derived from Gardenia jasminoides, which has been associated with anti-inflammatory, anti-angiogenic, and anti-proliferative effects; hypertension; and anti-ischemic brain injuries. However, the enhancement of oxaliplatin sensitivity by genipin remains unexplored. Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway. Importantly, the combination did not affect normal colon cells. BIM knockdown markedly inhibited apoptosis induced by the combination. In addition, genipin induced ROS by inhibiting superoxide dismutase 3 activity. These findings suggest that genipin maybe a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-18-0196 | - |
dc.identifier.scopusid | 2-s2.0-85064198805 | - |
dc.identifier.wosid | 000462996800003 | - |
dc.identifier.bibliographicCitation | Molecular Cancer Therapeutics, v.18, no.4, pp 751 - 761 | - |
dc.citation.title | Molecular Cancer Therapeutics | - |
dc.citation.volume | 18 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 751 | - |
dc.citation.endPage | 761 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ENDOPLASMIC-RETICULUM STRESS | - |
dc.subject.keywordPlus | ADVANCED PANCREATIC-CANCER | - |
dc.subject.keywordPlus | N-TERMINAL KINASE | - |
dc.subject.keywordPlus | III COLON-CANCER | - |
dc.subject.keywordPlus | STAGE-II | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | ADJUVANT THERAPY | - |
dc.subject.keywordPlus | CELL-DEATH | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.